L O A D I N G
July 1, 2014

Seragon is acquired by Genentech for up to $1.725 billion

A definitive agreement was executed with Genentech to acquire Seragon Pharmaceuticals for $725 million in cash up front along with $1 billion in contingent development milestone payments. Seragon was spun out of Aragon Pharmaceuticals following an acquisition of the company in 2013 by Johnson & Johnson for up to $1 billion ($650 million up front and $350 million in milestones). TCG was the largest shareholder of Seragon with an $8.4M total investment and a 24% stake at exit.